企業在運作的過程中，基於永續經營的概念，必須不斷追求進步。因此創新成為企業運作不可或缺。在現今競爭非常激烈，產品生命週期很短，變化速度極快的環境，我國製藥產業其創新的能力及動態的能力，即成為提昇競爭優勢及改善公司的經營績效最有效的利器之一。本研究採取個案研究，其研究結果如下：
一、本土藥廠在主從策略創新乃採取技術跟隨著國外藥廠的技術，著重於調適（而非創造）技術改變以降低製藥流程的風險及成本，培養出獨特能力；而組織流程創新適時調整組織架構及流程，使每位員工適時學習調整本身技能，以符合組織需要；在產品創新致力填補滿足客戶需求缺口，追求本身永續成長。
二、本土藥廠其組織管理程序，在轉型前的協調整合以欠缺水平溝通的定期主管會報、新產品開發會議等會議為主，轉型後包括策略聯盟進行協調整合；在學習部份，轉型前是被動、靜態，轉型後為知識型學習組織；在重整與轉變部份，轉變前面對環境變動，各部門抱持著事不關己的態度，轉變後定位為行銷導向藥品發展公司。
三、本土藥廠其企業專屬資產位置，在技術資產部份，轉型後聚焦在有利潤已開發成功之技術或產品；在互補資產部份，轉型前為具有技術合作能力，但對轉型方向受到技術的限制，轉型後包括研究發展、癌症科學發展事業及國際行銷能力；在企業商譽資產部份，轉型前沒有主力產品可以值得顧客及外界所稱道，轉型後其聲譽及品牌形象均良好。
四、本土藥廠其企業發展路徑，路徑相依部份，轉型過程依循過去模式進行；在技術機會部份，企業轉型過程中其核心技術影響企業的發展，但會適時調整。 / It is more urgent and important for Taiwan pharmaceutical companies to keep on improving innovation and dynamic capabilities to sustain growth , especially when they face more intense competitions , shorter-than-ever product life cycles, as well as more unpredictable environments . Based on case study method, the findings of the research are concluded as the following points.
First, Taiwan pharmaceutical companies concentrated more on the technical improvements than developing new technology ,for lower risks and higher cost efficiency in adopting new pharmaceutical manufacturing process. Regarding the adjustments in the process of organization , they focused on the cultivation of the unique capabilities of employees , upgrading innovation to capture the demand of clients.
Second, Taiwan pharmaceutical companies concentrated more on the coordination of the strategic alliance after transformation, than less efficient routine meetings for management and product development before transformation. They constructed the learning organization, in contrast to the previously passive and static patterns. They restructured organizations and positioned at the marketing-oriented pharmaceutical company after transformation, changing the indifferent culture among previous departments.
Third , Taiwan pharmaceutical companies developed more profitable and proved products after corporate transformation. Regarding the management of complementary assets, they removed the potential projects restrained by technical issues and adjusted to R&D, cancer-related projects and developing global marketing capabilities. After transformation, the reputation ,goodwill and brand image turned out to grow higher , in contrast to the absence of core products before.
Fourth, the roadmap of Taiwan pharmaceutical companies followed by the models in the past. As for the technical development, the core technology will influence the development of corporate transformation, but they would appropriately adjust it.
Keywords：Dynamic Capabilities、Pharmaceutical Company、Corporate Transformation、Innovation
| Identifer | oai:union.ndltd.org:CHENGCHI/G0097932068 |
| Creators | 許長禮 |
| Publisher | 國立政治大學 |
| Source Sets | National Chengchi University Libraries |
| Language | 中文 |
| Detected Language | English |
| Type | text |
| Rights | Copyright © nccu library on behalf of the copyright holders |
Page generated in 0.0014 seconds